KR970707272A - 신경 간세포 증식 조절 방법(regulation of neural stem cell proliferation) - Google Patents
신경 간세포 증식 조절 방법(regulation of neural stem cell proliferation)Info
- Publication number
- KR970707272A KR970707272A KR1019970703245A KR19970703245A KR970707272A KR 970707272 A KR970707272 A KR 970707272A KR 1019970703245 A KR1019970703245 A KR 1019970703245A KR 19970703245 A KR19970703245 A KR 19970703245A KR 970707272 A KR970707272 A KR 970707272A
- Authority
- KR
- South Korea
- Prior art keywords
- neural stem
- stem cells
- pluripotent
- composition
- regulatory factor
- Prior art date
Links
- 210000001178 neural stem cell Anatomy 0.000 title claims abstract description 10
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract 13
- 230000001105 regulatory effect Effects 0.000 claims abstract 11
- 239000000203 mixture Substances 0.000 claims abstract 8
- 230000001537 neural effect Effects 0.000 claims abstract 5
- 238000000338 in vitro Methods 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 210000002569 neuron Anatomy 0.000 claims description 3
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 229920002971 Heparan sulfate Polymers 0.000 claims 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- 108010059616 Activins Proteins 0.000 claims 1
- 102000007299 Amphiregulin Human genes 0.000 claims 1
- 108010033760 Amphiregulin Proteins 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 1
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 239000000488 activin Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 1
- 102000037983 regulatory factors Human genes 0.000 claims 1
- 108091008025 regulatory factors Proteins 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 239000003181 biological factor Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 시험관내 및 체내에서 다양한 생물학적인 인자를 포함하는 조성물을 사용하여 다능성 신경 간세포 증식을 조절하는 방법에 관한 것이다. 더욱 상세하게는, 본 발명은 신경 간세포를 분할시킴으로써 생성되는 전구세포의 수를 특이적 생물학적인 입자 또는 이들의 조합에 간세포를 노출시켜 조절하기 위한 방법 및 치료학적인 조성물에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 다능성 신경 간세포의 증식을 도시하는 개략도이다. (A) 증식성 인자의 존재하에서 상기 간세포는 분할하여 보다 많은 간세포 및 주기 세포로 구성되어진 비분화된 세포의 구체를 형성시킨다. (B) 비분화된 세포의 클론으로 유도된 구체가 비부착 기질상 및 증식성 인자의 존재하에 분해되어 단일 세포로서 플레이팅될 때, 각 간세포는 새로운 구체를 생성시킬 것이다. (C) 구체가 분화를 허용하는 조건에서 배양되면, 조기 세포는 뉴런, 성상세포 및 희소돌기아교세포내로 분화된다. 제2도(A)는 20ng/㎖ EGF중에 배양된 10-일 지난 뉴로스피어의 사진(100×배율)이다. (B)는 20ng/㎖ FGF중에 배양된 10-일 지난 뉴로스피어의 사진(100×배율)이다. (C)는 20ng/㎖ EGF+20ng/㎖ FGF중에 배양된 10-일 지난 뉴로스피어의 사진(100×배율)이다. 제3도는 20ng/㎖ EGF+20ng/㎖ FGF 또는 2㎛/㎖ FGF+20ng/㎖ 헤라판 황산염의 존재하에서 성장한 래트의 척수의 경부, 흉부, 및 요부 영역에서 유도한 일차 세포로부터 발생되는 뉴로스피어의 수를 도시하는 그래프이다.
Claims (15)
- (a) 뉴런, 성상세포 및 회소돌기아교세포로 분화될 수 있는 프로제니(progeny)를 생성시키는 하나 이상의 다능성 신경 간세포를 함유한 포유류 신경 조직을 해리시키는 단계, 및 (b) 간세포 증식을 유도하는 하나 이상의 증식성 인자 및 다능성 신경 간세포의 증식 및/또는 상기 다능성 신경 간소페 프로제니의 증식을 조절하는 조절 인자를 함유한 배양 배지내에서 다능성 신경 간세포를 증식시키는 단계를 포함하여, 다능성 신경 간세포 및/또는 상기 신경 간세포 프로제니의 시험관내 증식을 조절하는 방법.
- 제1항에 있어서, 증식성 인자가 EGF, 앰피레귤린(amphiregulin),aFGF, bFGF, 및 TGF α로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제1항에 있어서, 증식성 인자가 bFGF인 것을 특징으로 하는 방법.
- 제1항에 있어서, 조절 인자가 헤파란 황산염, CNTF, 레티노산, 액티빈, 인터루킨, 및 EGF로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
- 제3항에 있어서, 조절 인자가 헤파란 황산염인 것을 특징으로 하는 방법.
- 제3항에 있어서, 조절 인자가 EGF인 것을 특징으로 하는 방법.
- 제1항에 있어서, 다능성 신경 간세포가 포유류로부터 유도되는 것을 특징으로 하는 방법.
- 제1항에 있어서, 다능성 신경 간세포가 성인의 공여자로부터 유도되는 것을 특징으로 하는 방법.
- 제1항에 있어서, 간세포가 사람으로부터 유도되는 것을 특징으로 하는 방법.
- 제8항에 있어서, 간세포가 신경 질환을 앓고 있는 사람으로부터 유도되는 것을 특징으로 하는 방법.
- 환자의 CNS내의 신경 간세포의 증식을 조절하기 위한 치료학적인 조성물로서, 치료적으로 유효량의 신경 간세포 조절 인자를 포함하는 것을 특징으로 하는 조성물.
- 제11항에 있어서, 조절 인자가 신경 간세포의 증식을 억제하는 것을 특징으로 하는 조성물.
- 제12항에 있어서, 상기 조절 인자가 BMP-2, CNTF, 레티노산, TGF-β 및 MIP족의 일원, 및 EGF 및 FGF 수용체에 대항하는 앤티센스 올리고데옥시누클레오티드로 구성된 군으로부터 선택되는 것을 특징으로 하는 조성물.
- 제13항에 있어서, 상기 조절 인자기 BMP-2인 것을 특징으로 하는 조성물.
- 뇌 또는 척수가 손상된 환자에게서 반흔 조직 형성을 억제하기 위한 제12항 내지 제14항 중 어느 한 항의 조성물의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33873094A | 1994-11-14 | 1994-11-14 | |
| US08/338,730 | 1994-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970707272A true KR970707272A (ko) | 1997-12-01 |
Family
ID=23325929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019970703245A KR970707272A (ko) | 1994-11-14 | 1995-11-14 | 신경 간세포 증식 조절 방법(regulation of neural stem cell proliferation) |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0792350A1 (ko) |
| JP (1) | JPH10509592A (ko) |
| KR (1) | KR970707272A (ko) |
| CN (1) | CN1170435A (ko) |
| AU (1) | AU716811B2 (ko) |
| FI (1) | FI971956A (ko) |
| NO (1) | NO972171L (ko) |
| WO (1) | WO1996015226A1 (ko) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518606D0 (en) * | 1995-09-12 | 1995-11-15 | Inst Of Psychiatry | Neural transplantation |
| GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
| CA2266659A1 (en) * | 1996-11-15 | 1998-05-28 | Paule Poulin | Pretreatment with growth factors to protect against cns damage |
| US5968829A (en) * | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
| US6093531A (en) * | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
| US5958767A (en) * | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
| SE9804064D0 (sv) | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| US6238922B1 (en) * | 1999-02-26 | 2001-05-29 | Stemcells, Inc. | Use of collagenase in the preparation of neural stem cell cultures |
| GB9907243D0 (en) | 1999-03-29 | 1999-05-26 | Reneuron Ltd | Therapy |
| US6465215B1 (en) | 1999-12-14 | 2002-10-15 | Reneuron Limited | Identification of cells for transplantation |
| ATE473751T1 (de) | 2000-02-11 | 2010-07-15 | Schepens Eye Res Inst | Isolierung und transplantation von retinalen stammzellen |
| US20040034049A1 (en) * | 2000-10-05 | 2004-02-19 | Shigenori Okawa | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells |
| CA2460184A1 (en) | 2001-09-14 | 2003-03-27 | Stem Cell Therapeutics Inc. | Prolactin induced increase in neural stem cell numbers and therapeutical use thereof |
| US7129034B2 (en) | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
| AU2003216058A1 (en) | 2002-01-14 | 2003-07-30 | The Board Of Trustees Of The University Of Illinois | Mammalian neural stem cells, compositions and uses thereof |
| AU2003250697B2 (en) | 2002-07-30 | 2008-05-01 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
| KR100495532B1 (ko) * | 2002-09-18 | 2005-06-14 | 에프씨비파미셀 주식회사 | 간엽 간세포를 신경세포로 분화 및 증식시키는 방법 |
| US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
| US20040185429A1 (en) | 2002-12-09 | 2004-09-23 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
| WO2005040362A1 (en) * | 2003-10-29 | 2005-05-06 | Fcb Pharmicell Co., Ltd | Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease |
| JP4597538B2 (ja) * | 2004-02-03 | 2010-12-15 | 独立行政法人産業技術総合研究所 | 神経幹細胞増殖助剤及びこれを含んだ神経幹細胞用培地 |
| US7846898B2 (en) | 2004-02-13 | 2010-12-07 | Stem Cell Therapeutics Corp. | Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis |
| JP2008501356A (ja) | 2004-06-09 | 2008-01-24 | ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラ | 神経幹細胞 |
| GB0505510D0 (en) * | 2004-06-09 | 2005-04-27 | Univ Edinburgh | Neural stem cells |
| ES2294650T3 (es) | 2004-09-30 | 2008-04-01 | Reneuron Limited | Linea celular. |
| RU2434636C2 (ru) | 2004-11-17 | 2011-11-27 | Ньюралстем, Инк. | Трансплантация нервных клеток для лечения нейродегенеративных состояний |
| US8287853B2 (en) | 2005-02-11 | 2012-10-16 | Agency For Science, Technology And Research | Methods of culturing mesenchymal stem cells |
| CN101155913B (zh) * | 2005-02-11 | 2011-07-06 | 新加坡科技研究局 | 增殖干细胞的方法 |
| WO2007036033A1 (en) | 2005-09-27 | 2007-04-05 | Stem Cell Therapeutics Corp. | Oligodendrocyte precursor cell proliferation regulated by prolactin |
| CN1966080B (zh) * | 2005-11-17 | 2011-06-08 | 李凌松 | 一种治疗老年痴呆症、帕金森病的神经干细胞注射液 |
| JP2009530234A (ja) | 2006-03-17 | 2009-08-27 | ステム セル セラピューティクス コーポレイション | 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン |
| KR20080068352A (ko) * | 2007-01-19 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 생체외 모델에 의한 신경재생물질 탐색 방법 |
| JP2009278873A (ja) * | 2008-05-19 | 2009-12-03 | Japan Health Science Foundation | 培地および培養方法 |
| CN102325878A (zh) | 2008-12-23 | 2012-01-18 | 斯特姆塞尔思加利福尼亚有限公司 | 少突胶质前体细胞的靶向细胞群及制备与使用方法 |
| WO2011060135A1 (en) | 2009-11-12 | 2011-05-19 | Vbi Technologies, Llc | Subpopulations of spore-like cells and uses thereof |
| SG187226A1 (en) | 2010-07-28 | 2013-03-28 | Neuralstem Inc | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
| CN102839154A (zh) * | 2011-06-23 | 2012-12-26 | 上海安集协康生物技术有限公司 | 神经干细胞培养扩增方法及所用培养基 |
| BR112014019328A8 (pt) | 2012-02-17 | 2017-07-11 | The Schepens Eye Res Institute | Perfil de fenótipo de células progenitoras retinais humanas |
| US20170248581A1 (en) * | 2014-10-07 | 2017-08-31 | NuTech Medical, Inc. | Mesenchymal Stem Cell Diagnostic Testing |
| KR20190060016A (ko) | 2014-10-20 | 2019-05-31 | 뉴럴스템, 인크. | 성장 인자를 코딩하는 외인성 폴리뉴클레오티드를 포함하는 안정한 신경 줄기세포 및 그의 사용 방법 |
| CN104726407B (zh) * | 2014-11-24 | 2021-03-16 | 斯坦姆（天津）生物技术研究有限公司 | 一种利用器官培养以增加成年神经组织中神经干细胞收获率的方法 |
| CN105647868B (zh) * | 2014-12-04 | 2020-03-31 | 中国科学院大连化学物理研究所 | 一种利用表面微结构激活星形神经胶质细胞的方法 |
| JP6912789B2 (ja) * | 2016-03-16 | 2021-08-04 | 株式会社日本触媒 | 神経幹細胞の培養方法、およびニューロスフェロイドの形成方法 |
| CN106497879A (zh) * | 2016-11-07 | 2017-03-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种神经干细胞增殖和诱导其分化为多巴胺能神经元的培养基以及应用和增殖诱导方法 |
| CN108070558B (zh) * | 2017-11-24 | 2022-01-28 | 吉林省拓华生物科技有限公司 | 一种临床级神经干细胞的制备方法 |
| WO2020075534A1 (ja) * | 2018-10-11 | 2020-04-16 | 一丸ファルコス株式会社 | 神経幹細胞増殖用培地 |
| CN112779209B (zh) * | 2019-11-08 | 2023-01-24 | 合肥中科普瑞昇生物医药科技有限公司 | 原代乳腺上皮细胞培养基、培养方法及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5100668A (en) * | 1988-06-14 | 1992-03-31 | Massachusetts Institute Of Technology | Controlled release systems containing heparin and growth factors |
| EP0594669B9 (en) * | 1991-07-08 | 2008-03-19 | NeuroSpheres Holdings Ltd. | Growth factor-responsive neural progenitor cells which can be proliferated in vitro. |
| US5175103A (en) * | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
| WO1994003199A1 (en) * | 1992-08-04 | 1994-02-17 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
| DE69332147T2 (de) * | 1992-10-16 | 2002-12-12 | Neurospheres Holding Ltd., Calgary | Remyelination unter verwendung von neuronalen stammzellen |
| AU5367694A (en) * | 1992-10-28 | 1994-05-24 | Neurospheres Holdings Ltd | Biological factors and neural stem cells |
| ES2218524T3 (es) * | 1993-01-29 | 2004-11-16 | Neurospheres Holdings Ltd. | Modificacion genetica de celulas primordiales neurales. |
| WO1995013364A1 (en) * | 1993-11-09 | 1995-05-18 | Neurospheres Holdings Ltd. | In situ modification and manipulation of stem cells of the central nervous system |
-
1995
- 1995-11-14 CN CN95196842A patent/CN1170435A/zh active Pending
- 1995-11-14 JP JP8515600A patent/JPH10509592A/ja not_active Ceased
- 1995-11-14 WO PCT/CA1995/000637 patent/WO1996015226A1/en not_active Application Discontinuation
- 1995-11-14 EP EP95936393A patent/EP0792350A1/en not_active Withdrawn
- 1995-11-14 AU AU38367/95A patent/AU716811B2/en not_active Ceased
- 1995-11-14 KR KR1019970703245A patent/KR970707272A/ko not_active Application Discontinuation
-
1997
- 1997-05-07 FI FI971956A patent/FI971956A/fi unknown
- 1997-05-12 NO NO972171A patent/NO972171L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX9703492A (es) | 1997-10-31 |
| AU716811B2 (en) | 2000-03-09 |
| AU3836795A (en) | 1996-06-06 |
| FI971956A (fi) | 1997-07-04 |
| FI971956A0 (fi) | 1997-05-07 |
| NO972171D0 (no) | 1997-05-12 |
| CN1170435A (zh) | 1998-01-14 |
| WO1996015226A1 (en) | 1996-05-23 |
| JPH10509592A (ja) | 1998-09-22 |
| EP0792350A1 (en) | 1997-09-03 |
| NO972171L (no) | 1997-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970707272A (ko) | 신경 간세포 증식 조절 방법(regulation of neural stem cell proliferation) | |
| CA2307017C (en) | Erythropoietin-mediated neurogenesis | |
| Carpenter et al. | In vitro expansion of a multipotent population of human neural progenitor cells | |
| Kilpatrick et al. | Cloned multipotential precursors from the mouse cerebrum require FGF-2, whereas glial restricted precursors are stimulated with either FGF-2 or EGF | |
| Temple et al. | Stem cells in the adult mammalian central nervous system | |
| Toda et al. | Grafting neural stem cells improved the impaired spatial recognition in ischemic rats | |
| Kalcheim et al. | Neurotrophin 3 is a mitogen for cultured neural crest cells. | |
| Hicks et al. | Enriched environment enhances transplanted subventricular zone stem cell migration and functional recovery after stroke | |
| Rousselet et al. | Rat mesencephalic neurons in culture exhibit different morphological traits in the presence of media conditioned on mesencephalic or striatal astroglia | |
| Kilpatrick et al. | Cloning and growth of multipotential neural precursors: requirements for proliferation and differentiation | |
| Avellana‐Adalid et al. | Expansion of rat oligodendrocyte progenitors into proliferative “oligospheres” that retain differentiation potential | |
| AU715246B2 (en) | In vitro induction of dopaminergic cells | |
| Buc-Caron | Neuroepithelial progenitor cells explanted from human fetal brain proliferate and differentiatein vitro | |
| Kalcheim et al. | Brain-derived neurotrophic factor stimulates survival and neuronal differentiation in cultured avian neural crest | |
| Ali et al. | Collagen type IV promotes the differentiation of neuronal progenitors and inhibits astroglial differentiation in cortical cell cultures | |
| Yoshida et al. | Cytokines affecting survival and differentiation of an astrocyte progenitor cell line | |
| Baetge | Neural stem cells for CNS transplantation | |
| Vinores et al. | Class III β-tubulin in human retinal pigment epithelial cells in culture and in epiretinal membranes | |
| Eagleson et al. | Complementary distribution of collagen type IV and the epidermal growth factor receptor in the rat embryonic telencephalon | |
| Shetty et al. | Neurite outgrowth from progeny of epidermal growth factor–responsive hippocampal stem cells is significantly less robust than from fetal hippocampal cells following grafting onto organotypic hippocampal slice cultures: Effect of brain‐derived neurotrophic factor | |
| Sheedlo et al. | Influence of a retinal pigment epithelial cell factor (s) on rat retinal progenitor cells | |
| Moses et al. | Murine embryonic EGF-responsive ventral mesencephalic neurospheres display distinct regional specification and promote survival of dopaminergic neurons | |
| Rogister et al. | Cultured neurons release an inhibitor of astroglia proliferation (astrostatine) | |
| IANNOTTI | Neural stem cell transplantation in the repair of spinal cord injury | |
| Mokrý et al. | Differentiation of neural stem cells into cells of oligodendroglial lineage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |